Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Climb Bio, Inc.'s SEC filings document a Nasdaq-listed clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. The filings cover operating and financial results, Regulation FD pipeline disclosures, material-event reports and capital-structure information for common stock listed under the symbol CLYM.
Company filings also describe budoprutug and CLYM116 development disclosures, financing arrangements, executive and accounting officer changes, and governance matters presented in proxy materials. Proxy disclosures address director elections, auditor ratification, charter amendments, equity incentive plan provisions, stockholder voting procedures and other annual meeting matters.
Climb Bio, Inc. reported new preclinical results for its monoclonal antibody CLYM116, which targets APRIL and is being developed for IgA nephropathy. In a completed nonhuman primate study, CLYM116 showed deeper IgA reduction and a longer half-life compared with sibeprenlimab, a first-generation anti-APRIL antibody, suggesting a potential for less frequent dosing. Additional in vivo mouse studies showed enhanced APRIL elimination and antibody recycling versus sibeprenlimab.
The company plans, subject to regulatory clearance, to start a Phase 1 trial of CLYM116 in healthy volunteers in Q4 2025, with initial biomarker and dosing-interval data expected around mid-year 2026. Climb Bio is hosting a virtual investor event on September 29, 2025 to discuss these data, supported by a press release and presentation.
Schedule 13G: Pontifax-related entities report collective beneficial ownership of 5,206,380 shares of Climb Bio common stock, representing 7.7% of the class. The holdings are held in two limited partnerships (Pontifax (Israel) VI L.P. and Pontifax (Cayman) VI L.P.) controlled through Pontifax VI G.P. L.P. and Pontifax Management 4 G.P. (2015) Ltd., with Tomer Kariv and Ran Nussbaum identified as managing members. Reported power is shared voting and dispositive power over the full position; no sole voting or sole dispositive power is claimed.